Kathryn Davis, MD
Epilepsy · Philadelphia, PANPI 1073678181
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,690 of the $59,470 with a category attached, or 78.5%. It is spread thinly across 14 manufacturers, the largest accounting for just 23.0%. Among epilepsy clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $762.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$14K
- Eisai Inc.$10K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Neurelis, Inc.$5K
- UCB SA$5K
- UCB, Inc.$3K
- plus $12K from 8 others
Across 2 payments — averaging $17,368 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$35K
What the payments were for
- Consulting fees$46,69079%
- Speaking & faculty fees$5,3489%
- Travel & lodging$4,0067%
- Food & beverage$3,4286%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 19 | $13,656 |
| Eisai Inc. | 12 | $10,206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $9,385 |
| Neurelis, Inc. | 7 | $5,315 |
| UCB SA | 1 | $5,287 |
| UCB, Inc. | 9 | $3,374 |
| SK Life Science, Inc. | 6 | $3,254 |
| Biocodex, Inc. | 3 | $2,662 |
| Greenwich Biosciences, Inc. | 3 | $2,482 |
| Azurity Pharmaceuticals, Inc. | 2 | $2,250 |
| Vertex | 2 | $960 |
| Spark Therapeutics, Inc. | 1 | $485 |
| Jazz Pharmaceuticals Inc. | 1 | $117 |
| Medtronic | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS Neurostimulator Kit$13,217
- Fycompa$10,083
- VALTOCO$5,183
- Fintepla$3,138
- Cenobamate$2,800
- Epidiolex$2,599
- DIACOMIT$2,580
- ZONISADE$2,250
How this compares
$59,470 in reported general payments places this provider in the 95th percentile of 28 epilepsy providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 40 | $87,627 |
| OnfiClobazam | 19 | $72,399 |
| VimpatLacosamide | 31 | $59,072 |
| Keppra XrLevetiracetam | 25 | $50,722 |
| BriviactBrivaracetam | 21 | $45,187 |
| KeppraLevetiracetam | 12 | $33,258 |
| Topiramate ErTopiramate | 11 | $16,327 |
| NayzilamMidazolam | 11 | $10,810 |
| Clobazam | 71 | $7,956 |
| Lamotrigine ErLamotrigine | 15 | $6,235 |
| Lacosamide | 63 | $5,846 |
| Lamotrigine | 92 | $3,092 |
| Oxcarbazepine | 17 | $1,539 |
| Levetiracetam | 34 | $1,209 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Vimpat, Briviact, Nayzilam | $3,374 | $115,06963 claims |
| SK Life Science, Inc.Xcopri | $3,254 | $87,62740 claims |
| UCB SAKeppra | $5,287 | $33,25812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 epilepsy providers in Pennsylvania.
Other epilepsy in Philadelphia
- Michael GelfandPhiladelphia$50K
- Saurabh SinhaPhiladelphia$21K
- Ramya RaghupathiPhiladelphia$14K
- Erin ConradPhiladelphia$3K
- Taneeta GangulyPhiladelphia$2K
- Catherine KulickPhiladelphia$2K
- Genna WaldmanPhiladelphia$2K
- Itai LoushyPhiladelphia$845
- Daniel ZhouPhiladelphia$658
- Brian LittPhiladelphia$384
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.